Lignoceric Acid.
A very long chain saturated fat your own cells build and that oils supply in small amounts. It ends up inside the ceramides of the skin barrier and of nerve myelin.
- Category
- Fatty acid
What Lignoceric Acid is, and what it does.
- Does it work
- Mostly of interest to people reading a fatty acid panel or a ceramide formula. Peanut and rapeseed oil supply small amounts, and your own elongase enzymes make more.
- How much to take
- No daily amount is on record for it on its own, and it is rarely sold alone. In practice it arrives inside an oil or a ceramide blend rather than as a measured dose.
- Time to feel it
- There is no sensation timeline. Blood fatty acid patterns shift over weeks, and skin barrier lipids turn over on a similar scale.
- The first dose
- Day one is quiet. Whatever arrives is esterified straight into complex lipids rather than circulating free, so the change is a lipid measurement, not a feeling.
- With regular use
- Over weeks it feeds the ceramide pool of skin and nerve tissue. Your blood level reflects your own elongase activity as much as what you ate.
- How well tolerated
- It is a normal part of everyday cooking oils and food fats, so ordinary intakes are well tolerated. Isolated high doses have not been tested in people.
- How it feels
- There is nothing to sense. Its role is structural, inside membranes and the lipids of skin and nerve, which is measured rather than felt.
- The overlooked benefit
- Your blood level tracks how well your peroxisomes shorten it, not only what you ate, which is why it reads as a marker on specialist fatty acid panels.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Component of skin barrier and myelin ceramidesNarrative review
- Turnover by peroxisomal beta-oxidationNarrative review
- Blood levels linked to variation at elongase genesCohort study
- Dietary supply from plant oilsNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Ceramides are built from a sphingoid base amide-linked to a fatty acid, and in skin and nerve tissue that fatty acid is frequently a very long chain species including C24. Lignoceric acid is therefore a structural component of the ceramide pool rather than a separate additive. The two are not independent ingredients acting in parallel. Dietary supply of the free acid has not been shown to change tissue ceramide composition in humans.
Every two-carbon extension in fatty acid elongation uses malonyl-CoA, and malonyl-CoA is produced by the biotin-dependent carboxylation of acetyl-CoA. Without adequate biotin the whole elongation chain, including the steps that build C24, loses its substrate. This is textbook cofactor dependence and applies to all chain lengths. It is not a claim that supplemental biotin raises lignoceric acid levels.
Very long chain fatty acids are shortened in the peroxisome by an FAD-dependent acyl-CoA oxidase before the remainder is handed to mitochondria. FAD comes from riboflavin. The cofactor relationship is settled biochemistry and applies to the breakdown side rather than the synthesis side. It says nothing about whether supplementing riboflavin changes circulating levels of this fatty acid.
Peroxisomes cannot fully oxidise a very long chain fatty acid. They shorten it, then the medium chain product is conjugated to carnitine for transport into the mitochondrion where oxidation finishes. Carnitine is the shuttle for that handoff. This describes the normal metabolic route, not an effect of taking carnitine alongside this fatty acid.
Fatty acid elongases extend a range of substrates including both saturated very long chain species and the long chain omega-3 precursors. Supplementation studies that measure the full erythrocyte fatty acid profile report shifts across multiple species when omega-3 intake changes. Those are compositional markers, not clinical outcomes. Which direction any individual species moves depends on the baseline profile.
Barrier repair formulations combine several lipid classes because the skin barrier itself is a mixture of ceramides, cholesterol and free fatty acids. Very long chain saturated fatty acids sit in the free fatty acid fraction of that mixture. Squalane contributes a different, non-polar component. This is topical formulation reasoning rather than evidence for either ingredient taken orally.
A 24-carbon saturated fatty acid has a high melting point and essentially no water solubility, which makes it difficult to formulate and to absorb in free form. Phospholipid emulsification is the standard route to disperse such lipids. This is why the fatty acid usually appears as part of a natural fat or a phospholipid rather than as a free acid supplement. The point is formulation feasibility.
Nothing specific on file for Lignoceric Acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Lignoceric Acid actually does.
Lignoceric acid is a 24-carbon saturated fat, long enough to be classed as a very long chain fatty acid.
Your body makes it itself, adding two carbons at a time to shorter saturated fats through a family of elongase enzymes in the cell.
Because it's so long, it can't be burned directly in the mitochondria and has to be shortened first in a different part of the cell, so how well that process works governs how fast it's cleared.
It's a major building block of the fat molecules in nerve cell myelin and in the skin's outer barrier.
Where Lignoceric Acid comes from.
It comes from two places at once. A small amount is in oils like peanut and rapeseed, and your own cells also build it by adding carbon pairs onto shorter fats. Getting it on its own means splitting it out of an oil and separating it by melting point, which is why you almost never see it sold by itself.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Dietary supply comes largely as a minor fraction of peanut, rapeseed and some other seed oils. The body also makes it by elongating shorter saturated fatty acids.
Seed oils are pressed or solvent extracted, carrying the very long chain fraction along with the dominant fatty acids.
Where the isolated acid is needed, triglycerides are hydrolysed or transesterified to release free fatty acids or their esters.
The 24-carbon species is separated from shorter chain fatty acids by distillation or low-temperature crystallisation, exploiting the melting point difference.
Purity and chain length distribution are confirmed by gas chromatography of the fatty acid methyl esters.
Delivered as an isolated solid acid for analytical use, as an ester for processing, or left bound within a sphingolipid or whole oil for nutritional formats.
Getting Lignoceric Acid from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Genome-wide analysis identified genetic loci associated with circulating levels of very long chain saturated fatty acids including the C24 species.Cohort study. Lemaitre RN et al., 2015 (Journal of Lipid Research). PMID 25378659 ↗
- Pooled prospective data examined saturated fatty acid biomarkers, with very long chain species showing different association patterns from the shorter saturated fatty acids.Meta-analysis. Li Z et al., 2022 (Frontiers in Nutrition). PMID 36046138 ↗
- Twelve weeks of EPA and DHA supplementation with endurance training shifted the erythrocyte fatty acid profile across multiple species.Randomised trial. Tomczyk M et al., 2026 (Prostaglandins, Leukotrienes and Essential Fatty Acids). PMID 41349157 ↗
- Plasma fatty acid composition, including very long chain saturated species, changed with dietary macronutrient distribution.Randomised trial. Lundanes J et al., 2026 (Nutrition Journal). PMID 41808123 ↗
- Fatty acid intake and circulating levels were examined in relation to blood sugar status during pregnancy.Cohort study. Al Sinani M et al., 2026 (BMC Pregnancy and Childbirth). PMID 42067807 ↗
These are the studies our verdict leans on, chosen from the 5 we read for Lignoceric Acid. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.